Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs [0.03%]
用于转移性去势抵抗性前列腺癌的类固醇合成抑制剂opevesostat（MK-5684）：OMAH-A003和OMAH-A004试验设计
Evan Y Yu,Christian Gratzke,Mauricio Burotto et al.
Evan Y Yu et al.
Treatment options for metastatic castration-resistant prostate cancer (mCRPC) include androgen receptor pathway inhibitors (ARPIs), taxanes, radium-223, Lu-PSMA, poly (ADP-ribose) polymerase inhibitors, and immunotherapy in select patients....
Correction [0.03%]
改正错误
Published Erratum
Future oncology (London, England). 2026 Feb 20:1. DOI:10.1080/14796694.2026.2635169 2026
Gastric cancer occurrence and heterogeneity: integration of clinical data, multi-omics and tumor microenvironment [0.03%]
胃癌的发生和异质性：临床数据、多组学和肿瘤微环境的整合
Ping Li,Yafang Huang,Wanting Jiang et al.
Ping Li et al.
Gastric cancer (GC) is an epithelial malignant tumor with high morbidity and mortality. In recent years, more and more studies have strengthened our understanding of how GC develops, including the origin of GC cells, precancerous lesions, g...
Associations of systemic inflammatory markers with cancer survival outcomes: a systematic umbrella review [0.03%]
系统炎症标志物与癌症生存结局的相关性：系统伞状回顾分析
Sheng Li,Yan-Yu Zhu,Harry Asena Musonye et al.
Sheng Li et al.
Background: The systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) have been associated with poor cancer outcomes; however, no comprehensive evaluation across various cancer types has...
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer [0.03%]
作为晚期非小细胞肺癌总生存率替代指标的治疗反应达到时间和肿瘤最大消退时间的研究
Rachel Woodford,Sally Lord,Tom John et al.
Rachel Woodford et al.
Introduction: Objective response rate (ORR) is a common early endpoint in NSCLC trials, but its ability to predict overall survival (OS) is limited, especially for immunotherapy and targeted treatments. Alternative metric...
Validation of a blood-based autoantibody test to assess lung cancer risk in 4-30 mm pulmonary nodules: a retrospective pooled analysis of four cohort studies [0.03%]
基于血液的自身抗体检测评估4-30毫米肺结节肺癌风险的验证：四项队列研究的回顾性综合分析
Trevor J Pitcher,Kathryn J Long,Michael N Kammer et al.
Trevor J Pitcher et al.
Aim: To validate a blood-based autoantibody test (AAT) as a high specificity, rule-in biomarker for 4-30 mm indeterminate pulmonary nodules (IPN) across malignancy risk. ...
Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis [0.03%]
治疗转移性雄激素敏感前列腺癌的三联疗法和二联疗法的有效性和安全性：系统评价和贝叶斯网状meta分析
Jingqi Jiang,Yuhan Wang,Jiangtao Bai et al.
Jingqi Jiang et al.
Aim: To compare triple and dual therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC). Methods: A Bayesian network meta-analysis was conducted to indirectly compare overall survival, progression-free surv...
Radiomics analysis of MRI improves prediction of lymph node metastasis in laryngeal squamous cell carcinoma [0.03%]
基于MRI的影像组学分析可改善喉鳞癌淋巴结转移的预测能力
Bingying Li,Zaizai Cao,Jiangtao Zhong et al.
Bingying Li et al.
Objective: To explore the role of multi-sequence magnetic resonance imaging (MRI) images in preoperative prediction of lymph node metastasis in laryngeal squamous cell carcinoma (LSCC). ...
Evaluation of surgical treatment outcomes and development of a prognostic model for patients with small cell lung cancer [0.03%]
小细胞肺癌的外科治疗效果评估及预后模型构建
Penghu Gao,Hongbing Zhang,Jinghao Liu et al.
Penghu Gao et al.
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options. While surgery is increasingly considered for early-stage disease, its prognostic implications remain poorly characteriz...